Contribute Try STAT+ Today

After a defeat in federal court, the Department of Health and Human Services withdrew an advisory opinion which said drug makers participating in a controversial federal program must offer discounts through pharmacies that contract with hospitals serving low-income patients.

However, HHS simultaneously maintained the move does not have any bearing on a separate set of “violation” letters sent last month to six drug makers, which could face fines for failing to offer discounts through the 340B drug discount program for safety-net hospitals and clinics. The agency said the letters should be viewed as distinct from the opinion and that enforcement action can be pursued.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment